Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment

Launched by WUHAN UNION HOSPITAL, CHINA · Jun 17, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on using artificial intelligence (AI) to improve how we assess the risk of cancer and make decisions about diagnosis and treatment. The goal is to create a comprehensive medical database that includes important health information, such as clinical diagnoses, medical images, and other test results. By analyzing this data with advanced AI technology, researchers hope to enhance the accuracy of cancer screenings and treatment outcomes for patients with lung, stomach, or colorectal cancers.

To participate in this study, you may be eligible if you have suspected lung, stomach, or colorectal cancer or if you are a healthy individual with no known cancer diagnosis. Participants will need to provide detailed medical records and give consent to join the trial. If you decide to join, you can expect to contribute to important research that could lead to better cancer care in the future. The trial is currently recruiting participants of all genders, aged between 65 and 93 years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants with the suspected of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision
• • 2. Participants that have signed informed consent.
• • 3. Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.
• • 4. Healthy participants with no clinical diagnosis of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision.
• Exclusion Criteria:
• • 1. Participants with primary clinical and pathological data missing.
• • 2. Participants lost to follow-up.
• • 3. Participants with too poor medical image quality to perform segment and mark ROI accurately